目的 探討乳果糖口服溶液聯(lián)合谷氨酸鉀注射液治療肝性腦病的臨床療效。方法 選取2014年4月-2017年4月在天門市第一人民醫(yī)院治療的肝性腦病患者114例為研究對象，將所有患者隨機分為對照組和治療組，每組各57例。對照組靜脈滴注谷氨酸鉀注射液，60 mL加入到生理鹽水500 mL中，1次/d。治療組在對照組的基礎(chǔ)上口服乳果糖口服溶液，30 mL/次，3次/d。兩組患者均連續(xù)治療7 d。觀察兩組的臨床療效，比較兩組的生化學(xué)指標(biāo)和Child-Pugh評分。結(jié)果 治療后，對照組和治療組的總有效率分別為75.44%、92.98%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血氨、總膽紅素（TBil）、丙氨酸氨基轉(zhuǎn)移酶（ALT）和天門冬氨酸氨基轉(zhuǎn)氨酶（AST）水平均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些生化學(xué)指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組Child-Pugh評分均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組Child-Pugh評分明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 乳果糖口服溶液聯(lián)合谷氨酸鉀注射液治療肝性腦病具有較好的臨床療效，能改善精神狀況，降低血氨水平，改善肝臟功能，安全性較好，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Lactulose Oral Solution combined with Potassium Glutamate Injection in treatment of hepatic encephalopathy. Methods Patients (114 cases) with hepatic encephalopathy in the First People's Hospital of Tianmen from April 2014 to April 2017 were randomly divided into control and treatment groups, and each group had 57 cases. Patients in the control group were iv administered with Potassium Glutamate Injection, 60 mL added into normal saline 500 mL, once daily. Patients in the treatment group were po administered with Lactulose Oral Solution on the basis of the control group, 30 mL/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and biochemical indexes and Child-Pugh scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.44% and 92.98%, respectively, and there was difference between two groups (P < 0.05). After treatment, blood ammonia, TBil, ALT, and AST levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And biochemical indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, Child-Pugh scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the Child-Pugh score in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Lactulose Oral Solution combined with Potassium Glutamate Injection has clinical curative effect in treatment of hepatic encephalopathy, can improve the mental state, reduce blood ammonia levels, and improve liver function, with good safety, which has a certain clinical application value.